Business Context and Reporting Period
Company: AnaptysBio, Inc. (Nasdaq: ANAB)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: AnaptysBio is a clinical-stage biotechnology company developing immunology therapeutics for autoimmune and inflammatory diseases. Its lead asset, rosnilimab (a PD-1 agonist/depleter), is in Phase 2b trials for rheumatoid arthritis (RA) and Phase 2 for ulcerative colitis (UC). The company also holds a strategic collaboration with GlaxoSmithKline (GSK) for immuno-oncology assets, including Jemperli (dostarlimab).
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Collaboration Revenue | $91.3 million | $17.2 million |
| Net Loss | $(145.2) million | $(163.6) million |
| Research & Development Expenses | $163.8 million | $132.3 million |
| General & Administrative Expenses | $42.4 million | $41.9 million |
| Non-Cash Interest Expense (Royalty Sale) | $(50.1) million | $(18.1) million |
| Cash, Cash Equivalents & Investments | $420.8 million | $417.9 million |
| Liability for Sale of Future Royalties | $353.4 million | $310.8 million |
| Accumulated Deficit | $(759.3) million | $(614.1) million |
Material Changes vs. Prior Period
- Revenue Surge: Collaboration revenue increased 430% to $91.3 million, driven by $40.0 million in GSK sales milestones (Jemperli) and a $33.6 million increase in Jemperli royalty revenue.
- Improved Net Loss: Net loss narrowed by $18.4 million year-over-year, despite higher R&D spend, due to significantly higher revenue and interest income ($19.8 million vs. $18.9 million).
- R&D Spend Increase: R&D expenses rose $31.5 million, primarily due to a $28.4 million increase in external costs for the rosnilimab program and higher internal personnel costs.
- Financing Activity: The company raised approximately $93.9 million in net proceeds from a public offering in August 2024 and $50.0 million from an amendment to its Jemperli royalty monetization agreement in May 2024.
- Non-Cash Interest: Non-cash interest expense related to the sale of future royalties more than doubled to $50.1 million due to the Jemperli Amendment increasing the threshold of royalties sold to Sagard.
Guidance, Outlook, and Management Commentary
- Clinical Milestones: In February 2025, the company announced positive top-line data from the Phase 2b RA trial of rosnilimab, achieving its primary endpoint and showing statistical significance on key secondary endpoints. Data for the Phase 2 UC trial is expected in Q4 2025.
- Liquidity: Management believes existing cash, cash equivalents, and investments ($420.8 million) will fund operations for at least the next 12 months.
- Collaboration Updates:
- GSK: Jemperli sales by GSK grew >200% to $598.0 million in 2024. The company retains rights to a $75.0 million sales milestone if Jemperli annual net sales exceed $1 billion.
- Vanda Pharmaceuticals: In January 2025, AnaptysBio entered an exclusive license agreement for imsidolimab (GPP), receiving $10.0 million upfront and $5.0 million for drug supply, with up to $35.0 million in future milestones and 10% royalties.
- Risks: Key risks include the uncertainty of clinical trial outcomes for rosnilimab in UC, dependence on GSK for Jemperli commercialization, and the need for additional capital to fund future Phase 3 trials and commercialization efforts.
Key Facts for Investor Verification
- Rosnilimab Phase 2b Data: Verify the full clinical data release for the RA trial and the specific safety profile details to assess the likelihood of Phase 3 progression.
- Royalty Monetization Liability: Review the effective interest rate (22.7% as of Dec 31, 2024) and the sensitivity of the $353.4 million liability to changes in Jemperli sales forecasts.
- Cash Burn Rate: Monitor the quarterly cash burn rate given the $163.8 million R&D spend to confirm the 12-month liquidity runway.
- Immidololmab Deal Terms: Confirm the specific regulatory milestones triggering the $35.0 million in potential future payments from Vanda Pharmaceuticals.
- Section 382 Limitations: Note that $186.1 million of federal NOLs are subject to annual limitations due to prior ownership changes, which may restrict future tax benefits.